Lilly stops promoting cancer drug after shock trial failureShares in Eli Lilly were down in early trading after the US drugmaker said its cancer drug Lartruvo Share XLilly stops promoting cancer drug after shock trial failurehttps://pharmaphorum.com/news/lilly-pulls-cancer-drug-from-market-after-shock-trial-failure/
Lilly’s CEO looks to M&A, but not for CAR-T or gene therapiesEli Lilly’s CEO David Ricks could sign more deals to strengthen its pipeline of cancer drugs, but is Share XLilly’s CEO looks to M&A, but not for CAR-T or gene therapieshttps://pharmaphorum.com/news/lillys-ceo-looks-to-ma-but-not-for-car-t-or-gene-therapies/
Lilly focuses on tau with AC Immune Alzheimer’s R&D tie-upEli Lilly has paid $81m to develop drugs targeting aggregation of tau proteins associated with Alzheimer’s with Swiss Share XLilly focuses on tau with AC Immune Alzheimer’s R&D tie-uphttps://pharmaphorum.com/news/lilly-focuses-on-tau-with-ac-immune-alzheimers-rd-tie-up/
Novo Nordisk’s diabetes pill clears cardiac safety hurdleNovo Nordisk is set to file its daily semaglutide type 2 diabetes pill after it cleared a phase Share XNovo Nordisk’s diabetes pill clears cardiac safety hurdlehttps://pharmaphorum.com/news/novos-diabetes-pill-clears-cardiac-safety-hurdle-filings-to-follow/
Lilly files new class migraine drug with FDAEli Lilly has filed a new migraine drug, lasmiditan, with the US regulator, the first drug in its Share XLilly files new class migraine drug with FDAhttps://pharmaphorum.com/news/lilly-files-new-class-migraine-drug-with-fda/
Teva slumps after Express Scripts funds migraine rivals in USA major prescription benefit manager in the US will not reimburse Teva’s preventative migraine drug Ajovy (fremanezumab), in Share XTeva slumps after Express Scripts funds migraine rivals in UShttps://pharmaphorum.com/news/teva-slumps-after-express-scripts-funds-migraine-rivals-in-us/
Lilly unveils promising data from dual-action diabetes drugEli Lilly’s investigational diabetes drug has shown early promise as a possible aid to overcoming obesity in trial Share XLilly unveils promising data from dual-action diabetes drughttps://pharmaphorum.com/news/lilly-diabetes-unveils-promising-data-from-dual-action-diabetes-drug/
Lilly’s breast cancer drug Verzenio approved in EUEli Lilly’s Verzenio breast cancer drug has been approved in Europe, as the pharma prepares to compete with Share XLilly’s breast cancer drug Verzenio approved in EUhttps://pharmaphorum.com/news/lillys-breast-cancer-drug-verzenio-approved-in-eu/
Novo to market ‘connected’ insulin pens next yearNovo Nordisk is to launch “connected” insulin pens, responding for demands from patients for devices able to communicate Share XNovo to market ‘connected’ insulin pens next yearhttps://pharmaphorum.com/news/novo-to-market-connected-insulin-pens-next-year/
